1-(4-硝基苯基)硝酸胍 | 142992-72-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-硝基苯基)硝酸胍
• 英文名称: N-(4-nitrophenyl)guanidine nitrate
• 英文别名: 4-nitrophenylguanidine nitrate；4-nitrophenylguanidinium nitrate；N-(4-nitrophenyl)guanidinium nitrate；1-(4-nitrophenyl)guanidine nitrate；(4-Nitro-phenyl)-guanidin; Nitrat；1-(4-Nitrophenyl)guanidine nitrate；nitric acid;2-(4-nitrophenyl)guanidine
• CAS: 142992-72-1
• 化学式: C₇H₈N₄O₂*HNO₃
• 分子量: 243.179
• InChiKey: REOYYGKJQOLCPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.15
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  176
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 包装等级：
  III
• 危险类别：
  5.1
• 危险性防范说明：
  P501,P270,P220,P210,P221,P264,P280,P370+P378,P337+P313,P305+P351+P338,P302+P352,P332+P313,P362,P301+P312+P330
• 危险品运输编号：
  1479
• 危险性描述：
  H302,H315,H319,H272
• 储存条件：
  室温下应存放在干燥密封的环境中。

反应信息

• 作为反应物：
  描述：

  1-(4-硝基苯基)硝酸胍 在 sodium hydroxide 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (4-Nitro-phenyl)-{4-[4-(piperazine-1-sulfonyl)-phenyl]-pyrimidin-2-yl}-amine
  参考文献：
  名称：

  A novel series of potent and selective IKK2 inhibitors

  摘要：

  A novel series of ammopyrimidine IKK2 inhibitors have been developed which show excellent in vitro inhibition of this enzyme and good selectivity over the IKK1 isoform. The relative potency and selectivity of these compounds has been rationalized using QSAR and structure-based modelling. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.10.047
• 作为产物：
  描述：

  氰胺 、 4-硝基苯胺 在 硝酸 作用下， 以 乙醇 、 水 为溶剂， 150.0 ℃ 、2.0 MPa 条件下， 以19%的产率得到1-(4-硝基苯基)硝酸胍
  参考文献：
  名称：

  通过“切割和胶水”策略设计的7-（2-苯胺基嘧啶-4-基）-1-苯并ze庚因-2-酮是双重Aurora A / VEGF-R激酶抑制剂

  摘要：

  尽管蛋白激酶的过表达和过度活跃是导致多种人类癌症的原因，但目前被批准用作抗癌药物的蛋白激酶抑制剂仅能解决其中几种酶的问题。为了确定解决替代蛋白激酶的新化学型，将已知的PLK1 / VEGF-R2抑制剂类别的基本结构进行了正式解剖并重新组装。合成了所得的7-（2-苯胺基嘧啶丁-4-基）-1-苯并ze庚因-2-酮，并证明是Aurora A激酶和VEGF受体激酶的双重抑制剂。与Aurora A配合的新化学型的两个代表的晶体结构显示了ATP结合口袋中的配体取向，并为合理的结构修饰提供了基础。具有连接的磺酰胺取代基的同类物保留了Aurora A的抑制活性。

  DOI：

  10.3390/molecules26061611

文献信息

• N-Phenyl-N,N"-Guanidinedicarboxylic Acid Esters. Synthesis, Anthelmintic and Pesticidal Effects
  作者：Karel Palát、Milan Čeladník、Jaroslav Daněk、Štefan Varkonda

  DOI：10.1135/cccc19921127

  日期：——

  Substituted phenylammonium chlorides react with cyanamide to give the corresponding phenylguanidines which on treatment with chloroformate esters give N-subst.phenyl-N,N"-guanidinedicarboxylic acid esters. All substances prepared have been tested for their anthelmintic activity against the model helminths Nippostrongylus brasilienses and Hymenolepis nana var. fraterna. The most significant activity has been found with diethyl N-(4-nitrophenyl)-N,N"-guanidinedicarboxylate. In pesticidal screening the compounds have shown fungicidal activity and particularly ovicidal activity against Tetranychus urticae which activity is increased with the compounds having a nitro group in the benzene ring.

  苯基铵氯化物与氰胺反应生成相应的苯基胍，经氯甲酸酯处理后得到N-取代苯基-N,N"-胍二羧酸酯。所有制备的物质均已对模拟寄生虫尼波强气虫和小绦虫fraterna进行了驱虫活性测试。其中，二乙基N-(4-硝基苯基)-N,N"-胍二羧酸酯表现出最显著的活性。在杀虫剂筛选中，这些化合物表现出杀真菌活性，特别是对网纹叶螨具有卵杀活性，这种活性随着苯环中含有硝基基团的化合物而增加。
• [EN] N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF<br/>[FR] DERIVES DE N-PHENYL-2-PYRIMIDINE-AMINE ET PROCEDE DE PREPARATION DE CEUX-CI
  申请人：IL YANG PHARM CO LTD

  公开号：WO2004099186A1

  公开（公告）日：2004-11-18

  The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on tumor, lung cancer, gastric cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound and a pharmaceutical composition for the prevention and treatment of such diseases as tumor, lung cancer, gastric cancer, etc., which comprises the compound as an active ingredient.

  本发明涉及一种对温血动物的肿瘤、肺癌、胃癌等具有优越效果的N-苯基-2-嘧啶胺衍生物及其盐。本发明还涉及一种制备该化合物的方法和一种药物组合物，用于预防和治疗肿瘤、肺癌、胃癌等疾病，其包括该化合物作为活性成分。
• [EN] N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF<br/>[FR] DERIVES DE N-PHENYL-2-PYRIMIDINE-AMINE ET PROCEDE D'ELABORATION CORRESPONDANT
  申请人：IL YANG PHARM CO LTD

  公开号：WO2004099187A1

  公开（公告）日：2004-11-18

  The present invention relates to an N-Phenyl-2-pyrimidine-aminine derivative showing a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or accute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer or cervical cancer, etc. of warm blooded animals and its salt. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various disease, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

  本发明涉及一种对暖血动物的肺癌、胃癌、结肠癌、胰腺癌、肝癌、前列腺癌、乳腺癌、慢性或急性白血病、血液恶性肿瘤、脑瘤、膀胱癌、直肠癌或宫颈癌等表现出优越效果的N-苯基-2-嘧啶-胺衍生物及其盐。本发明还涉及一种制备该化合物的方法，以及一种用于治疗上述各种疾病的药物组合物，其包括作为活性成分的该化合物的有效量，以及药学上可接受的惰性载体。
• N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
  申请人：IL YANG PHARM. CO., LTD.

  公开号：US20040248918A1

  公开（公告）日：2004-12-09

  The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

  本发明涉及一种对温血动物的肺癌、胃癌、结肠癌、胰腺癌、肝癌、前列腺癌、乳腺癌、慢性或急性白血病、血液恶性肿瘤、脑膨出、膀胱癌、直肠癌或宫颈癌等表现出优越效果的N-苯基-2-嘧啶胺衍生物及其盐。本发明还涉及一种制备该化合物的方法，以及一种用于治疗上述各种疾病的药物组合物，其中包括作为活性成分的该化合物的有效量，以及药用可接受的惰性载体。
• Phenylamino-Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)
  作者：Jürg Zimmermann、Giorgio Caravatti、Helmut Mett、Thomas Meyer、Marcel Müller、Nicholas B. Lydon、Doriano Fabbro

  DOI：10.1002/ardp.19963290707

  日期：——

  Phenylamino‐pyrimidines represent a novel class of inhibitors of the protein kinase C with a high degree of selectivity versus other serine/threonine and tyrosine kinases. Steady state kinetic analysis of N‐(3‐[1‐imidazolyl]‐phenyl)‐4‐(3‐pyridyl)‐2‐pyrimidinamine (5), which showed potent inhibitory activity, revealed competitive kinetics relative to ATP. The adjacent H‐bond acceptor of the pyrimidine

  苯氨基嘧啶是一类新型的蛋白激酶 C 抑制剂，与其他丝氨酸/苏氨酸和酪氨酸激酶相比具有高度选择性。N-(3-[1-咪唑基]-苯基)-4-(3-吡啶基)-2-嘧啶胺(5)的稳态动力学分析显示出有效的抑制活性，揭示了相对于ATP的竞争动力学。发现与苯胺的 H 键供体相邻的嘧啶部分的相邻 H 键受体对抑制活性至关重要。N-(3-Nitro-phenyl)-4-(3-pyridyl)-2-pyrimidinamine (7) 优先抑制 PKC-α (IC50 = 0.79 μM) 而不是其他测试的亚型。PKC-α 的抑制常数与对 T24 人膀胱癌细胞的抗增殖作用呈定性相关，但也有一些例外。